logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 9 of 9 Items
Showing 1 - 9 of 9 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Letter

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, Hayrapetyan A,  et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Letter

Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis

Cox HS, Sibilia C, Feuerriegel S, Kalon S, Polonsky JA,  et al.
2008-11-27 • New England Journal of Medicine
2008-11-27 • New England Journal of Medicine
Journal Article
|
Research

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N,  et al.
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...
Journal Article
|
Letter

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen

Achar J, Berry C, Herboczek K, Parpieva N, Tillashaykhov M,  et al.
2015-09-09 • Emerging Infectious Diseases
2015-09-09 • Emerging Infectious Diseases
Journal Article
|
Research

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

Bonnet MMB, Bastard M, du Cros PAK, Khamraev AK, Kimenye K,  et al.
2016-02-01 • International Journal of Tuberculosis and Lung Disease
2016-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not avail...
Journal Article
|
Research

Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan

Kohler S, Asadov DA, Bründer A, Healy S, Khamraev AK,  et al.
2016-07-12 • Health Economics Review
2016-07-12 • Health Economics Review

Uzbekistan inherited a hospital-based health system from the Soviet Union. We explore the health system-related challenges faced during the scale-up of ambulatory (outpatient) treatme...

Journal Article
|
Research

Ambulatory tuberculosis treatment in post-Semashko health care systems needs supportive financing mechanisms

Kohler S, Asadov D, Brunder A, Healy S, Khamraev AK,  et al.
2014-12-01 • International Journal of Tuberculosis and Lung Disease
2014-12-01 • International Journal of Tuberculosis and Lung Disease
The tuberculosis (TB) control strategy in the Republic of Karakalpakstan, Uzbekistan, is being changed to decentralised out-patient care for most TB patients by the Government of Uzbekis...
Journal Article
|
Research

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

Trauer JM, Achar J, Parpieva N, Khamraev AK, Denholm JT,  et al.
2016-11-18 • BMC Medicine
2016-11-18 • BMC Medicine
BACKGROUND
Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and o...
Journal Article
|
Research

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

du Cros PAK, Khamraev AK, Tigay Z, Abdrasuliev T, Greig J,  et al.
2021-02-08 • ERJ open research
2021-02-08 • ERJ open research
BACKGROUND
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment....